Our partners at MassBio recently released its 2024 Biopharma Funding & Pipeline Report which includes full-year data on venture capital investment, IPOs, and mergers & acquisitions, as well as drug pipeline statistics and FDA approvals.
According to the report, Massachusetts-headquartered biopharma companies received $7.89 billion in venture capital (VC) funding, marking the first year-over-year increase since the pandemic, according to a newly released year-end report from biopharma member organization MassBio.
